Oracle Cancer Trust has generously supported a number of pioneering head and neck research projects at The Institute of Cancer Research, awarding over £1m in grants over the past five years to support PhD students and Post-Doctoral Researchers.
Head and neck cancer is hugely underfunded compared to incidence and Oracle have made significant breakthroughs with the ICR in discovering smarter, kinder treatments for patients. Oracle funds early-stage studies that show the greatest promise of being translated into full clinical trials.
Oracle funds a variety of studies including a thyroid cancer research group, immuno and virus therapies, imaging, combination drug therapies and developing treatment algorithms for the new MR Linac imaging machine based at The Royal Marsden Hospital in Sutton.
Developing new treatment strategies
Professor Kevin Harrington, who supervises a number of Oracle’s projects says:
“The partnership between the ICR and Oracle allows researchers to develop an array of new treatment strategies which have the potential to make a real difference for patients with head and neck and thyroid cancers.
“In particular, Oracle has the courage and foresight to support innovative approaches from their inception through to the point where researchers are able to win competitive funding from major grant-awarding bodies. In this regard, Oracle is making a unique contribution to changing the research landscape for patients with head and neck cancers.”
Oracle relies on donations from patients, supporters, grants and trusts to support its research programmes and is the UK’s largest medical research charity dedicated to funding research into head and neck cancer.
Head and neck cancer is one of the fastest forms of cancer and is the sixth most common type of cancer in the UK.